2023.6.30
041
177
字数：3200+
Azitra是一家临床阶段医学皮肤病治疗服务商，Azitra通过将微生物组的功能与分子遗传学结合起来，致力于利用生物疗法来治疗皮肤疾病，包括癌症相关皮疹、Netherton综合征、特应性皮炎和寻常型鱼鳞病。近日在美交所上市。
Azitra的产品管线包括两个活体生物治疗产品候选和一个用于精准皮肤学的蛋白质候选物，该公司预计将于2023年开始进行其工程微生物ATR-12用于Netherton综合征的首次人体试验。主要有：①ATR-12
Theraclion是一家医疗器械公司，专注于为良性肿瘤患者开发超声波无创治疗方案，该公司是世界上唯一一家为乳腺腺纤维瘤和良性甲状腺疾病患者提供无创治疗方案的公司。近日，FuruiParis将使用自有资金700万欧元通过认购Theraclion定向增发的股份和认股权证对其进行增资，每股认购价格约为0.577欧元。
Theraclion成立于2004年，是一家法国肿瘤治疗设备研发商，专注于为良性肿瘤患者开发超声波无创治疗方案，开发了一个名为Echopulse的设备，该设备结合了高强度聚焦超声波（HIFU）治疗和实时超声波监测，可以用于对良性肿瘤患者进行非侵入性治疗和非卧床性治疗。此前，在2019年，Theraclion获得了来自Unigestion的3650万欧元的A轮融资。本轮投资商FuruiParis成立于1978年，是法国巴黎的一个纺织品品牌，总部位于法国巴黎的18区。FuruiParis品牌注重创新和品质，致力于为客户提供高质量的产品和服务。
MediView XR是一家医疗XR服务商，致力于为外科医生提供增强现实图像，从而有效地帮助他们带来类似3D X射线的视觉感知能力。借助微软HoloLens或其他AR头显，外科医生在把相关医疗器械插入患者体内后就能看到逼真的数字影像，其可以精确地显示器械在皮肤之下的画面。AR外科手术导航平台工具将以类似于控制游戏的方式帮助外科医生清除癌瘤。近日完成1500万美元战略融资，由 Mayo Clinic、Cleveland Clinic、GE HealthCare、JobsOhio Capital Growth Fund、Inside View 和 KKVS Syndicate 投资，并额外承诺下一轮融资。
OncoResponse是一家医疗科技服务商，主要研发免疫肿瘤抗体。近日获得了1400万美元的新融资，投资者包括RiverVest Venture Partners、ARCH Venture Partners、Canaan Partners、3B Future Health Fund、Bering Capital、Takeda Ventures、InterVest等。
Led by CEO Clifford Stocks, OncoResponse is a clinical-stage, immuno-oncology biotech company developing cancer immunotherapies using clues from the immune systems of Elite Cancer Responders. In a broad strategic alliance with MD Anderson Cancer Center, OncoResponse deploys a proprietary B-cell discovery platform to identify and develop novel antibodies targeting immune cells in the tumor microenvironment.
Its lead clinical candidate, OR2805, is a fully human antibody discovered using B cells derived from an Elite Responder to checkpoint inhibitor (CPI) therapy. OR2805 has entered cohort expansion trials in multiple cancer indications. Additional pipeline candidates that modulate suppressive macrophage activity are under development, including OR502, an anti-LILRB2 antibody that rescues innate and adaptive immune responses from LILRB2-mediated immune suppression. OR502 will enter clinical studies in 2023.
Myeloid Therapeutics是一家美国细胞免疫癌症疗法研发商，是专注于研发癌症新疗法的mRNA免疫治疗公司，包括使用自体细胞疗法，使用mRNA进行体内细胞编程，以及使用RetroT™进行基于RNA的基因编辑。近日完成7300万美元融资，由Hatteras Investment Partners领投，包括Newpath Partners、8VC和Alexandria Venture Investments在内的所有现有投资者参与，另有新投资者ARCH Venture Partners和Moore Strategic Ventures的加入。
The company intends to use the funds for the continued clinical development of MT-101, its lead cell therapy program in Phase 1/2 for T cell lymphoma, and accelerate the development of MT-302, a FIC TROP2-FcA mRNA-LNP product,into a Phase 1/2 study for TROP2-expressing tumors.Additional in vivo programming candidates are also advancing to the clinic.
Led by CEO Daniel Getts,Myeloid Therapeutics is a clinical stage mRNA-immunotherapy company developing novel therapies for cancer.Integrating the fields of RNA, immunology and medicine,the company’s proprietary platform provides clinical solutions by matching therapeutic modalities to disease conditions, including use of autologous cell therapies, in vivo cell programming using mRNA, and RNA-based gene-editing using RetroT.
MT-101 is the company’s first autologous CAR monocyte.This candidate was derived from the Company’s proprietary ATAK™ platform and designed to harness the ability of myeloid cells to penetrate into tumors and promote broad anti-tumor activity.MT-101 targets CD5,a surface receptor that is present in greater than 75% of peripheral T cell lymphomas.To create MT-101, the patient’s cells are engineered ex vivo with the mRNA-strand coding for the CAR.The engineered cells are delivered back to the patient with a vein-to-vein time of eight days.The ATAK™ CAR is proprietary to Myeloid and manufactured using the Company’s patented processes.
The Company’s lead in vivo program,MT-302,is a TROP2-targeting in vivo CAR designed for expression within the myeloid compartment.TROP2 is a tumor associated antigen expressed widely on epithelial tumors,including some of the most difficult to treat cancers.Treatment with MT-302 has demonstrated monotherapy activity in a TROP2/TNBC model,confirming the potency of programmed myeloid cells in the absence of T cells.Myeloid believes that MT-302 has significant advantages over TROP2-ADC approaches through its ability to engage the full immune response.In 2023,Myeloid expects to initiate a Phase 1/2 clinical study with MT-302 for patients with TROP2-expressing tumors.
3、B轮及以后
Tissium, a Paris, France and Boston, MA-based medtech company developing biomorphic programmable polymers for tissue reconstruction, raised $50M in Series D funding.The round saw participation from Fonds Stratégique des Transitions, managed by ISALT, Merieux Developpement and returning Cathay Health, Credit Mutuel Innovation and Sofinnova Partners.
The company’s technology is based on research and intellectual property from the laboratories of Professor Robert Langer (MIT) and Professor Jeffrey M. Karp (Brigham and Women’s Hospital), who cofounded Tissium in 2013.Led by CEO Christophe Bancel, Tissium is a MedTech company dedicated to the development and commercialization of products derived from its proprietary family of fully biosynthetic, biomorphic, and programmable polymers to address multiple unmet clinical needs, including atraumatic tissue repair and reconstruction.
Currently, the company has a pipeline of seven products across three verticals, including sutureless nerve repair, hernia repair and cardiovascular sealants. Each product is designed to enhance the tissue reconstruction process. In addition, Tissium develops complementary delivery and activation devices for enhanced performance and usability of its products.
ElevateBio是一家细胞及基因治疗技术研发商，重点关注免疫疗法、再生医学和基因疗法。该公司打造了一个完全整合的业务模式，旨在为基因和细胞疗法开发公司提供资金、研发基地，以及药物开发和商业化知识。近日完成了4.01亿美元D轮融资。
The round was led by AyurMaya Capital Management Fund, managed by Matrix Capital Management, and joined by a group of new and existing investors. Its syndicate now includes new investors Woodline, Lee Family Office (Asia), and R&D partner Novo Nordisk, as well as existing investors: Matrix Capital Management, The Invus Group, Emerson Collective, SoftBank Vision Fund 2, Fidelity Management & Research Company, MPM Capital, F2 Ventures, Redmile Group, EcoR1 Capital, Samsara BioCapital, Surveyor Capital (a Citadel company), EDBI, Vertex Ventures, and iTochu,. In connection with the financing, Khalil Barrage, Managing Director of The Invus Group, was appointed to ElevateBio’s Board of Directors.
ElevateBio并不是一个“单纯”的生物技术公司，研发和搭建专有生产管线，而更像是一个平台型公司，不断孵化该细分领域内不同的新公司。这种模式将专业团队、资源和资本整合在一起，与科学创始人、医疗中心和企业家们合作不断推出新公司。孵化公司有Allovir、HighPassBio和Life Edit等。The company intends to use the funds to further advance its technology platforms Life Edit and BaseCamp.
Led by CEO David Hallal, ElevateBio is a technology-driven company built to power the development of transformative cell and gene therapies. Its integrated technologies model offers scale and biotechnological capabilities to power cell and gene therapy processes, programs and companies to their full potential. Its ecosystem combines multiple R&D technology platforms – including Life Edit, a full-spectrum gene-editing platform; a proprietary induced pluripotent stem cell (iPSC) platform, and an RNA, cell, protein, and vector engineering platform – with BaseCamp, its end-to-end genetic medicine cGMP manufacturing and process development business, to power the discovery and development of advanced therapeutics. In addition, ElevateBio is also building a pipeline of cellular, genetic, and regenerative medicines.
In connection with Novo Nordisk’s investment in the Series D financing, ElevateBio’s integrated subsidiary Life Edit Therapeutics also announced a multi-target collaboration with Novo Nordisk to discover and develop base editing therapies. In addition to the equity investment, Life Edit will receive an upfront cash payment and is eligible to receive potential development, regulatory, and commercial milestones of $250-$335 million for each of the seven programs under the collaboration. Life Edit also has an option to opt into a global profit share for one program.
Quanta Therapeutics是一家美国小分子抗癌药物研发商，专注于基于RAS靶点的肿瘤治疗，率先采用靶向疗法治疗RAS驱动的癌症。近日获得5070万美元的D轮融资。此次融资由Avidity Partners领投，并得到了包括Sofinnova Investments、Vida Ventures、Surveyor Capital 、Longitude Capital、BVF Partners以及AbbVie Ventures在内的Quanta Therapeutics现有投资者的支持，新参与的投资者包括GC&H Investments和WS Investment Company。
Led by Perry Nisen, MD, PhD, Chief Executive Officer, Quanta Therapeutics is a biopharmaceutical company focused on the most prevalent and elusive target in oncology—RAS. Its vision is to develop novel small molecule cancer medicines by selectively targeting protein-protein interactions that are key to oncogenic RAS activity. Its team has extensive drug development expertise and substantial research experience in the RAS space. By applying innovative medicinal chemistry and its protein conformation detection technology, Quanta aims to advance differentiated RAS programs that address the resistance paradigms of targeted therapy in oncology.
The company intends to use the funds to (support advancement of two KRAS inhibitor programs into the clinic in 2024.) advance its pipeline, including:①Two chemically distinct allosteric KRAS inhibitors, QTX3034, a multi-KRAS inhibitor, and QTX3046, a G12D-selective KRAS inhibitor. These programs are currently in Investigational New Drug Application (IND)-enabling studies to support anticipated clinical trial initiation in KRAS-driven solid tumor indications in 2024.②A novel RAF1 discovery program employing direct allosteric modulation of the active RAS-RAF1 membrane signaling complex to selectively target a broad spectrum of RAS-driven tumors with the potential for kinase-independent synthetic lethality.Additional discovery programs with undisclosed targets, including combination partners for Quanta’s lead programs.
VarmX是荷兰一家生物制药公司，致力于开发和制造治疗性蛋白质，以立即恢复出血患者的血液凝固。主要产品PseudoXa是一种修饰的重组人凝血因子X，能够在直接Xa因子抗凝剂(DOACS)如利伐沙班、阿哌沙班和依多沙班的存在下立即恢复血液凝固。近日完成B+轮3000万欧元融资，由Sound Bioventures牵头，而欧洲创新委员会 (EIC) 基金也作为新投资者加入。支持者包括现有投资者EQT Life Sciences（前身为 LSP）、Inkef、Lundbeckfonden BioCapital、Ysios Capital、BioGeneration Ventures (BGV)、InnovationQuarter (IQ) 和Libertatis Ergo Holding (LEH)。
Founded in 2016 by Professor Pieter Reitsma as a spin-off from the Leiden University Medical Center (LUMC), and led by Dr. Jan Öhrström, CEO, VarmX is advancing its lead compound called VMX-C001, a modified recombinant blood factor X being developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy.The company intends to use the funds to obtain investigational new drug (IND) approval for its lead compound VMX-C001 and to complete preparations for the pivotal clinical trial, including large scale manufacturing.
